Abbott Laboratories (ABT) is due to report first-quarter 2026 results before the market opens on April 16, 2026, according to the company’s earnings-date announcement. As of April 14, 2026, Yahoo Finance showed Abbott shares trading near the $100 mark, implying a market value of roughly $176 billion.
What Wall Street Expects
Wall Street expects Abbott to post first-quarter 2026 revenue of about $11.02 billion and adjusted earnings per share of $1.14. Abbott’s first-quarter 2025 earnings release said the company generated $10.36 billion of sales and adjusted diluted EPS of $1.09 in the year-ago quarter. Framed that way, the setup is for another quarter of mid-single-digit growth rather than a dramatic upside surprise.
That matters because the stock’s near-term debate is no longer about pandemic-era volatility. Investors are trying to gauge whether Abbott’s portfolio mix is becoming cleaner and more durable as COVID testing fades from the comparison base. A modest beat alone may not be enough to move sentiment if the underlying segment mix looks weaker than expected.
Medical Devices and Diagnostics Are the Main Swing Factors
Abbott’s fourth-quarter 2025 report said Medical Devices remained the main growth engine, led by diabetes care and other device categories. That has made Libre, structural heart, and rhythm-management commentary central, heading into the April print. Investors will want proof that device momentum is still strong enough to carry companywide growth even if some of Abbott’s slower-growing businesses remain uneven.
Diagnostics is the more sensitive piece. Abbott’s recent earnings materials said the company was still working through the runoff in COVID-testing revenue, while emphasizing improvements in the underlying base diagnostics business. That distinction is important. If first-quarter 2026 results show that routine diagnostics demand and instrument utilization are firming, investors are likely to view the segment as moving closer to a more normal earnings profile.
If that does not happen, the market could keep treating Diagnostics as a drag on valuation even if Abbott meets consensus on revenue and adjusted EPS. In other words, the report is likely to be judged more on the quality of growth than on the headline numbers alone.
Nutrition and Established Pharmaceuticals Still Matter
Abbott’s broader diversification has helped cushion the transition away from COVID-related diagnostics. The company’s recent annual filing and earnings releases show that Nutrition and Established Pharmaceuticals remain meaningful contributors to the revenue base, particularly outside the United States. Those segments are not usually the first thing the market focuses on before an Abbott earnings report, but they still shape how investors think about margin quality and geographic balance.
Nutrition is worth watching because a stable result there would reinforce the idea that Abbott’s portfolio is not relying solely on devices. Established Pharmaceuticals is also important because it gives Abbott exposure to branded generics in international markets, although that business can be affected by currency swings and local pricing conditions.
For that reason, investors will likely look past the simple top-line print and ask whether growth is broadening across the portfolio. A quarter that shows devices staying strong while Nutrition and Established Pharmaceuticals remain stable would strengthen the view that Abbott’s earnings base is becoming more dependable.
Key Signals for Investors
- Whether Abbott keeps device-led growth intact, especially in diabetes care and structural heart.
- Whether Diagnostics shows enough non-COVID improvement to support a cleaner margin outlook.
- Whether Nutrition and Established Pharmaceuticals remain stable enough to support the group mix.
- Whether management reaffirms or tightens its 2026 outlook after the first-quarter print.